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Fanconi anaemia (FA) is an inherited disease with congenital and developmental abnormalities, bone marrow failure, and extreme
risk of leukemic transformation. Bone marrow surveillance is an important part of the clinical management of FA and often
reveals cytogenetic aberrations. Here, we review bone marrow findings in FA and discuss the clinical and biological implications
of chromosomal aberrations associated with leukemic transformation.
1. Introduction
Fanconi anemia (FA) is an inherited disease with bone
marrow failure, variable congenital and developmental
abnormalities, and extreme cancer predisposition. The
most common malignancies in FA are myeloid leukemia
and squamous cell carcinoma. On a cellular level, FA is
characterized by chromosomal instability and cross-linker
sensitivity, which is the diagnostic hallmark of FA. For
diagnostic testing, this is determined by demonstration of
hypersensitivity to mitomycin C (MMC) or diepoxybu-
tane (DEB) of patient derived peripheral blood cells or
fibroblasts [1–3]. FA cells also display hypersensitivity to
proapoptotic stimuli of certain cytokines, such as TNF-α
and IFN-γ, which has been implicated in haematological
manifestations of FA [4–6]. Cell cycle analysis of FA cells
shows a characteristic arrest in the G2 phase, which is
exacerbated by exposure to MMC [7–9]. This clinical and
cellular phenotype results from a defect in a DNA damage
response (DDR) pathway (FA/BRCA pathway), in which
FA and associated proteins interact. So far, 15 FA genes
(FANCA, FANCB, FANCC, FANCD1/BRCA2, FANCD2,
FANCE, FANCF, FANCG, FANCI, FANCJ, FANCL, FANCM,
FANCN/PALPB2, FANCO/RAD51C, and FANCP/SLX4) have
been identified that can be mutated in FA [2, 10–12], of
which FANCA, FANCG, and FANCC are the most commonly
mutated genes in studied FA populations [2]. Importantly,
the discovery that mutations in BRCA2 causes FA in the
subgroup FA-D1, which comprises less than 5% of all FA
patients, linked the FA DNA damage response pathway to
hereditary breast and ovarian cancer (HBOC) [13, 14].
Hematopoiesis in the bone marrow (BM) is the most
commonly affected organ system in FA, and most FA patients
will develop clinically relevant hematological complications
in their first or second decades of life [15]. BM complications
of FA can manifest with hypoplasia, often initially being
limited to thrombocytopenia in peripheral blood counts,
or general aplasia. When the diagnosis of FA is made,
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which might happen with considerable delay, bone marrow
appearances can already be more advanced and consistent
with myelodysplasia. In FA, this often presents as refractory
cytopenia with multilineage dysplasia, with or without excess
of blasts on morphologic evaluation. Common morpho-
logic abnormalities on bone marrow examination include
irregular nuclear contours, budding nuclei, and karyorrhexis
[16]. In some patients, the diagnosis of FA is only made
on presentation with overt myeloid leukemia. How common
undiagnosed FA presents with AML is not known, but FA
should be considered especially in young patients with AML,
even in the absence of sometimes only subtle congenital
malformations such as short stature and microcephaly, in
particular when excess toxicity or prolonged aplasia after
chemotherapy of extreme toxicity is encountered [17–19].
Less than ten cases of lymphoblastic leukemias have been
reported in FA, which have been mostly of T-lineage,
and appear to be limited to patients with mutations in
FANCD1/BRCA2 and FANCD2 [19–21].
Given the high incidence of hematological complications
of FA, BM surveillance for morphological and cytogenetic
changes makes an important contribution to the clinical
management of FA patients. With improved and more
sensitive methods for the detection of chromosomal aber-
rations over the last decade, and better understanding of
clinical implications of BM cytogenetic findings in general
for preleukemic changes and the diagnosis and management
of hematological malignancies, FA bone marrow surveillance
provides important information for clinical decision making.
In addition, clonal evolution and associated chromoso-
mal aberrations in FA are important for understanding
malignant transformation in general and therefore wider
implications. Here, we review bone marrow chromosomal
aberrations in FA and discuss the clinical and biological
implications.
1.1. Bone Marrow Surveillance: Clinical Aspects for Patient
Management. In view of the relative infrequency and clinical
variety of FA, no evidence-based data exist on how and how
frequent bone marrow should be surveyed in FA patients.
In view of variable practice, a recent survey carried out in
the UK (S. Meyer, unpublished data), confirmed broadly
the recommended practice, in that FA patients with normal
blood counts should have at least a yearly assessment of
bone marrow morphology and cytogenetics [3, 22]. If there
is evidence of bone marrow failure, most centers would
consider increasing the frequency and monitor more closely
for appearance and evolution of chromosomal aberrations.
For the initial management planning at diagnosis, it is
worth considering that absent radius and a severe phenotype
is statistically associated with earlier bone marrow failure,
and that of the most commonly mutated genes, FANCG
and FANCC have a statistically higher incidence of early
hematological complications than FANCA [23]. However,
BM failure is a common presentation of FA caused by
mutations in all complementation groups. Surveillance for
FA-associated BM manifestations should include morphol-
ogy and assessment of cellularity as well as cytogenetic
evaluation [3]. The cytogenetic evaluation should include
conventional karyotyping. Importantly, however, cytogenetic
analysis should specifically include investigations for FA-
characteristic chromosomal aberrations as outlined below.
Only with the application of more sophisticated cytogenetic
methodologies the incidence and significance of FA-specific
aberrations can be determined. These would include routine
application of or/and comparative genomic hybridization
(CGH) or more sensitive whole genome analysis such as
array CGH, in addition to fluorescent in situ hybridization
(FISH), targeting FA-specific chromosomal gains and losses
on a single cell level.
1.2. Spectrum of FA-Specific BM Chromosomal Aberrations.
Clonal bone marrow aberrations in individuals affected
by FA were first reported as far back as the 1970s and
early 1980s, when several studies recognized cytogenetic
abnormalities on bone marrow examination of FA patients,
many of them noting a high frequency of monosomy
7, detected by conventional karyotyping [25, 26]. The
clinical observation that the detectability of chromosomal
aberrations in bone marrow aspirates of FA patients can
vary over time, with clones becoming transiently unde-
tectable, has led to an underestimation of clinical relevance
of chromosomal aberrations in FA [27]. In addition, the
absence of nonrandom chromosomal rearrangements that
are frequently found in AML in particular in childhood,
has delayed the recognition and the clinical and prognostic
significance of specific aberrations frequently seen in FA
[24]. A better understanding of the clinical relevance and
biological implications of chromosomal aberrations in FA
was achieved over the last decade by analysis of larger case
series and the application of modern molecular cytogenetic
technologies in addition to conventional karyotyping [16,
28–31]. This has led to the identification and delineation
of specific patterns of chromosomal aberrations in FA. In
contrast to aberrations seen in sporadic AML in childhood,
these are characteristically unbalanced, with gains and losses
of chromosomal material during clonal evolution. Frequent
for FA are gains of the chromosomal regions 1q and 3q,
as illustrated in Figure 1, and partial or complete loss of
chromosome 7 [16, 29–33]. Of these, 3q gains are in
particular characteristic of FA. By studying larger numbers
of FA patients sequentially, not only the high specificity
for FA became evident, but also the clinical implication of
3q gains, of which occurrence indicate transformation to
MDS and AML [30, 31]. In four independent studies, two
from Europe and two from North America, the association
of 3q gains with progression to or presence of FA-related
myelodysplasia was confirmed [16, 29–31]. Importantly,
gains involving 3q are only rarely seen in BM from non-
Fanconi patients [34–36], while balanced chromosomal
aberrations, such as inversions or translocations involving
the 3q are well documented in myeloid malignancies from
non-FA patients, in particular in adults [35, 36]. Therefore,
cytogenetic detection of 3q gains in apparently sporadic
cases of MDS or AML would indicate testing for FA. The
impact on gene expression resulting from FA-specific gains
in the area of common amplification, 3q26-3q29, has only








Figure 1: FA-associated 3q aberrations. (a) conventional cytogenetics: outcuts of chromosome 2, 3, and 6 showing additional material at
2q, normal chromosomes 3, and an apparent deletion of 6q. (b) the conventional CGH shows a slight deviation at 2q, a gain of 3q25 to
3qter (enh), and a loss of material from 6q23 to 6qter (dim). (c) the FISH with whole chromosome paints wcp3 und wcp6 demonstrates
two cell lines: one with material of chromosome 6 translocated to 2q and with material of 3 translocated to 6q; another cell line which
carries only the translocation of material of chromosome 3 to 6q. Thus, the apparent deletion detected by conventional cytogenetics proved
to be not a sole deletion of 6q but in addition a unbalanced translocation of 3q onto 6q. In addition, the patient had a monosomy 7
(data not shown). The karyotype according to ISCN 2009 in bone marrow cells was 45,XY,-7[2]/45,der(6)(6pter→ 6q22::3q25→ 3qter),-
7[27]/45,der(2)(2pter→ 2q37::6q22→ 6qter),der(6)(6pter→ 6q22::3q25→ 3qter),-7[8].
transcriptional regulator EVI1 (ecotropic viral integration
site 1) for leukaemic transformation in FA [37, 38]. Another
frequently observed aberration in FA is gain of chromosomal
material at 1q. This aberration can also be present in
morphologically relatively normal BM and is a finding also
in non FA-hematological diseases. Its presence is often the
sole finding in the early stages of clonal evolution and can
persist for years, but also occurs frequently with 3q gains
and other aberrations. Chromosomal aberration involving
chromosome 7 include -7/-7q, which, as in the non-FA
population, is significantly correlated with more advanced
dysplasia and commonly part of a clone with a more
complex karyotype that frequently also shows gain of 3q
material [39]. Sequential analysis of clonal progression in FA
has revealed that 3q-gains often precede changes involving
partial or whole loss of chromosome 7 [30, 37]. Another
more recently recognized frequent finding in FA-associated
clonal evolution is 11q-in advancing FA-associated MDS.
This lesion occurs in FA frequently with a more complex
karyotype that also shows 3q gain and/or -7 [31]. The
recent detection of involvement of the RUNX1 locus at 21q
in FA-associated genomic abnormalities, which in all cases
were associated with advanced MDS [31], has also some
important biological implications for the understanding of
clonal evolution with FA, which is discussed below. Gains
and losses of chromosomal material can also involve other
chromosomes, but not with the same FA-specific patterns as
for 3q. Balanced translocations have been described in FA,
and occur usually as part of more complex clonal rearrange-
ments. Single cases also had involvement of the 3q region
as well a single report of an 11q23 translocation [21, 38].
Importantly, common balanced nonrandom chromosomal
rearrangements that are seen in AML, such as t(8; 21) or
inv(16) translocations, have never been reported in FA [24].
1.3. Clonal FA-Associated Bone Marrow Aberrations: Clinical
Implications. Hematological complications are the most
common manifestation of FA. Over the last three decades
according to large studies carried out in North America
and Europe, the cumulative incidence of any hematological
abnormality in FA approaches 90%, and the cumulative
incidence of leukemia has been approximately 30% by 40
years of age [20, 23]. Therapeutically, options to treat bone
marrow failure in FA are limited to interventions with growth
factors and androgens in order to improve peripheral blood
counts [3], but this does not alter the high risk of leukemic
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transformation. The most important management decision
for hematological complications of FA is when and how to
proceed to hematopoietic stem cell transplantation (HSCT).
The outcome of HSCT in FA has improved dramatically [40,
41], and the incidence and survival patterns quoted above,
as well the clinical course of FA are changing accordingly
[23]. Many centers would elect HSCT for FA in the presence
of significant hematological abnormalities and availability of
a suitable donor. Cytogenetic information would certainly
inform decision making, and the presence of chromosomal
aberrations, in particular those associated with high risk of
malignant transformation would potentially justify a more
aggressive approach that could include partly mismatched
donors [41, 42]. Leukemia in FA is very difficult to treat.
From sparse published data of relatively few reported cases,
overt leukemia in FA is associated with poor prognosis and
short survival. Conditioning regimes for FA have empirically
been tailored for the intrinsic chemosensitivity of FA patients
and are increasingly based on fludarabine with low-dose
cyclophosphamide. There is little evidence that the presence
of BM cytogenetic aberrations should influence conditioning
regimes, as long as there is no evidence of overt leukemia.
However, numbers of reported cases are very small [40, 41,
43], and several cases of leukemic relapse after HSCT have
been reported, of which intriguingly one was from donor
cells [44].
1.4. FA-Characteristic Chromosomal Aberrations: Implications
for Malignant Transformation. The emergence of charac-
teristic patterns of chromosomal aberrations in FA has
relevance for the management of FA patients. Detection
of chromosomal aberrations that confer a high risk of
transformation to MDS and AML warrants a more aggressive
approach in order to prevent leukemia development. How-
ever, the study of chromosomal aberrations in this disorder
has some more generally relevant implications, giving insight
of secondary events in clonal evolution arising associated
with an inherited defect in the DNA damage response.
The FA-characteristic clonal evolution with dominance of
chromosomal gains and losses is likely to be a specific
result of the disruption of the FA/BRCA pathway and
at least partially caused by FA-related unresolved DNA
damage during S phase. This unresolved DNA damage is
thought to lead to the FA-specific G2 arrest and could lead
to the accumulation double-strand breaks and switch to
more error-prone repair by nonhomologous end joining.
Indeed, nonhomologous end joining is largely efficient
in FA cells in contrast to homologous repair, which is
grossly impaired in FA [45–47]. However, this possible and
extremely simplified explanation could only partly explain
the occurrence of aberrations, but not characteristic patterns
of chromosomal aberrations involving typically 3q and 1q.
The striking overrepresentation of 1q and 3q could imply
that these chromosomal regions are particularly susceptible
to FA/BRCA disruption-associated damage. An alternative
or additional explanation would be that resulting genetic
changes confer a growth advantage, possibly in particular
in the presence of a defect in the FA/BRCA pathway.
Cytogenetic analysis of sporadic AMLs that occur in a
comparable age group of older children and young adults
shows some marked differences when compared with FA-
associated leukaemic transformation, exemplified by the
rarity of any 3q aberrations in less than 5% of childhood the
AML in the NPO studies and the MRC trials [48, 49], and
exceedingly rare findings of gains of chromosomal material
in this region, implying an alternative pathogenesis of FA-
associated leukaemic transformation. The FA-characteristic
3q gains nearly always harbor one of the most aggressive
leukemogenic oncogenes, EVI1, which was first detected
to be amplified and overexpressed as an initial event in
FA-derived AML transformation in patient material and
cell lines from a patient with biallelic FANCD1/BRCA2
mutations [16, 31, 38] and subsequently shown to result
in overexpression of EVI1 [37]. This suggest that FA-
associated leukemia shares its biology with one of the most
aggressive forms of sporadic AML [35, 36]. Intriguingly,
EVI1 overexpression in childhood AML, which has been
detected in approximately 10% of cases, is normally not a
result of chromosomal rearrangements of the 3q region, but
appears to be associated other chromosomal rearrangements
and is not of the same prognostic relevance as EVI1
overexpression resulting from chromosomal rearrangements
[50]. The other specific gene that appears to be targeted
by FA-associated chromosomal rearrangements is RUNX1,
which points to the question as to how chromosomal
rearrangements in FA promote leukemic transformation.
One important observation comes from studies with FANCC
-/- mice. Leukaemic clones in bone marrow of these mice
that were outgrown under the selective pressure of TNF-
α showed abrogated cytokine sensitivity occurring together
with chromosomal aberrations [51]. In addition, analysis of
patient derived BM cells of FA patients with chromosomal
aberrations led to the detection of an attenuated cellular FA
phenotype. Cells with this phenotype maintained lack of
FANCD2 ubiquitination associated with FA core complex
gene mutations, and MMC hypersensitivity, but did not
display the FA-specific G2 arrest on cell cycle analysis [28].
It will be important to explore to what extent and by which
mechanism individual or combined the genetic changes
associated with leukemic transformation in FA modulating
the cellular FA phenotype. Taken together, these observations
point to a modulatory effect mediated by chromosomal
aberrations on the cellular FA phenotype, which is likely to
be of general relevance for oncogene-mediated malignant
progression and the DNA damage response [52].
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